Author:
Kondo Masahide,Hoshi Shu-Ling,Yamanaka Takeharu,Ishiguro Hiroshi,Toi Masakazu
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. The Japanese Breast Cancer Society (2009) Zenkoku nyugan kanjya touroku chousa houkoku—zanteiban—dai 38 gou 2007 nenji shourei (National breast cancer registry report—provisional edition—No. 38 2007 cases). The Japanese Breast Cancer Society, Tokyo
2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and endocrine therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717
3. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel members (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol 20(8):1319–1329
4. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826
5. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734